4D Molecular Therapeutics, Inc. (FDMT)

In October 2025, the stock price rose due to a strategic collaboration with Otsuka Pharmaceutical and an equity investment from the Cystic Fibrosis Foundation. In November 2025, Kristian Humer was appointed as the Chief Financial Officer. In December 2025, positive interim Phase 1 clinical data for 4D-710 in cystic fibrosis was announced, but analysts expressed criticism. In January 2026, the company provided a company update and anticipated development milestones for 2026, noting that enrollment in its 4D-150 Phase 3 wet AMD clinical trials was exceeding expectations. In February 2026, the company completed enrollment for the 4FRONT-1 Phase 3 clinical trial of 4D-150 in wet AMD ahead of initial projections. In March 2026, the company reported its full-year 2025 financial results, highlighting a strengthened balance sheet, but shares declined after updated data from an early-stage trial for its cystic fibrosis therapy, 4D-710, was released. In April 2026, a sell signal was issued from a pivot top point.

As a clinical-stage biotechnology company, 4D Molecular Therapeutics' revenue generation is primarily driven by collaboration agreements, milestone payments from partnerships, and financing activities, rather than direct product sales to consumers. Therefore, the company's products and services do not exhibit traditional demand seasonality.

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company focused on developing next-generation AAV vectors and product candidates using its Therapeutic Vector Evolution platform. The company's research and development efforts are primarily focused on ophthalmology, cardiology, and pulmonology. Major product candidates include 4D-150 for retinal vascular diseases, 4D-710 for cystic fibrosis lung disease, 4D-175 for geographic atrophy, 4D-725 for alpha-1 anti-trypsin deficiency lung disease, 4D-125 for X-linked retinitis pigmentosa, 4D-110 for choroideremia, and 4D-310 for Fabry disease.

4D Molecular Therapeutics' core operations are primarily based in Emeryville, California, USA. While its physical operational footprint is U.S.-based, the company's impact is global through international clinical trial sites and strategic collaborations, such as the agreement with Otsuka Pharmaceutical Co., Ltd. for Asia-Pacific markets.

4D Molecular Therapeutics' brand reputation has been shaped by its clinical development progress and financial performance. Positive developments, such as the rapid enrollment in Phase 3 trials for 4D-150 and the strategic partnership with Otsuka, have contributed positively to its standing. Analyst downgrades following the interim Phase 1 data for 4D-710 in cystic fibrosis indicate some skepticism regarding the clarity of efficacy, despite the company's positive outlook. Overall, the company maintains a "Moderate Buy" consensus rating from analysts.

Institutional investors hold a significant stake in 4D Molecular Therapeutics, with ownership ranging from approximately 49% to 74.60% of the company's stock. Major institutional owners include Ra Capital Management, Janus Henderson Group Plc, Bvf Inc/il, Goldman Sachs Group Inc, BlackRock, Inc., Novo Holdings A/S, Vanguard Group Inc, State Street Corp, Armistice Capital, Llc, and Federated Hermes, Inc. Individual insiders also own shares, with CEO David Kirn holding 3.0% of the shares outstanding as of November 2025.